The restrictions on Novavax's vaccine could portend changes at the FDA. Commissioner Marty Makary suggested last week that ...

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...

Novavax Inc. jumped in early trading after US regulators fully approved its Covid vaccine, easing investors’ concerns after ...

(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...

Investors reacted positively to the news, as the FDA’s approval not only enhances Novavax’s product offering but also solidifies its partnership with Sanofi, a key player in the vaccine market. The ...

Germany's antitrust head Andreas Mundt on Monday addressed mounting concerns about the deviation in approaches between ...

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to ...

The vaccine will only be available to those at high risk from COVID—excluding those who may need it to protect a relative or ...

Asia market update: US sovereign downgrade and Apple/Alibaba news are among the focal points; UST yields rise, curve steepens; US equity FUTs lag; USD weakens slightly. - US collateral requirements in ...

JN.1, a variant of Omicron BA.2.86, emerged in late 2023 with 30 immune-evasion mutations. It spreads more efficiently due to ...

The US Food and Drug Administration approved Novavax's COVID-19 vaccine, but limited its use to older adults and people over ...

This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the ...